×
About 11,020 results

ALLMedicine™ Sarcomas Center

Research & Reviews  3,834 results

Metastatic High-Grade Endometrial Stromal Sarcoma with BCOR Translocation to the Pleura...
https://doi.org/10.1177/10668969221098093
International Journal of Surgical Pathology; Gonsalves C, Ross J et. al.

May 17th, 2022 - Sarcomas in cytology fluids are uncommon, accounting for an estimated 3-6% of malignant effusions. High-grade endometrial stromal sarcomas are uncommon malignancies, whose true frequency is not well defined. We present a case of high-grade endomet...

Fever and Systemic Inflammatory Response Syndrome After Wide Resection of Pediatric Bon...
https://doi.org/10.1097/BPO.0000000000002181
Journal of Pediatric Orthopedics; Gallaway KE, Atadja LA et. al.

May 14th, 2022 - While postoperative fever is common and thought to be physiological, data is limited in pediatric patients with bone sarcomas. Understanding the predictive value of postoperative fever and systemic inflammatory response syndrome (SIRS) in this pop...

Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma incl...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092704
BMC Cancer; Kawai A, Narahara H et. al.

May 14th, 2022 - Soft tissue sarcomas (STSs) are a heterogeneous group of cancers with over 100 described subtypes. While these cancers are infrequent, the prognosis is quite poor, particularly for those with stage IV metastatic disease. Patients for whom curative...

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04890093

May 13th, 2022 - Background: Irinotecan is a prodrug of an inhibitor of topoisomerase 1 (active metabolite is SN-38) with known activity in sarcomas, however it has limitations including suboptimal bioavailability and systemic side effects including severe diarrhe...

see more →

Guidelines  16 results

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagno...
https://doi.org/10.1016/j.annonc.2021.08.1995
Annals of Oncology : Official Journal of the European Soc... Strauss SJ, Frezza AM et. al.

Sep 10th, 2021 - Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.|2021|Strauss SJ,Frezza AM,Abecassis N,Bajpai J,Bauer S,|diagnosis,epidemiology,therapy,diagnosis,epidemiology,therapy,diagnosis,ep...

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines f...
https://doi.org/10.1016/j.annonc.2021.07.006
Annals of Oncology : Official Journal of the European Soc... Gronchi A, Miah AB et. al.

Jul 26th, 2021 - Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.|2021|Gronchi A,Miah AB,Dei Tos AP,Abecassis N,Bajpai J,|diagnosis,epidemiology,therapy,diagnosis,epidemiology,therapy,

SEOM Clinical Guideline of management of soft-tissue sarcoma (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057970
Clinical & Translational Oncology : Official Publication ... de Juan Ferré A, Álvarez Álvarez R et. al.

Jan 7th, 2021 - Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory ...

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatme...
https://doi.org/10.1093/annonc/mdy310
Annals of Oncology : Official Journal of the European Soc... Casali PG, Bielack S et. al.

Oct 5th, 2018 - Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2018|Casali PG,Bielack S,Abecassis N,Aro HT,Bauer S,|methods,standards,standards,therapeutic use,diagnosis,epidemiology,pathology,therapy,diag...

see more →

Drugs  27 results see all →

Clinicaltrials.gov  144 results

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04890093

May 13th, 2022 - Background: Irinotecan is a prodrug of an inhibitor of topoisomerase 1 (active metabolite is SN-38) with known activity in sarcomas, however it has limitations including suboptimal bioavailability and systemic side effects including severe diarrhe...

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Retroperitoneal Sarcomas (TORNADO)
https://clinicaltrials.gov/ct2/show/NCT04968106

May 11th, 2022 - This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (1:1) phase II trial. Patients will be randomized between arm A (neodjuvant chemotherapy by doxorubicin + ifosfamide) and arm B (neodjuvant chemotherapy by doxorub...

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT03449901

May 11th, 2022 - The investigators have recently demonstrated that argininosuccinate synthase 1 (ASS1) expression is silenced in 88% of all sarcomas (n=708), and that this loss is associated with a decreased overall survival. Using the extracellular arginine deple...

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
https://clinicaltrials.gov/ct2/show/NCT05180695

May 11th, 2022 - This trial is a two-step Phase I/II study comprising: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination (N= up to 30 patients). The dose escalation will be conducted according to a sequential and adaptive...

Localized Leiomyosarcoma Biomarker Protocol
https://clinicaltrials.gov/ct2/show/NCT04925089

May 9th, 2022 - Leiomyosarcoma (LMS) is one of the more common soft tissue sarcomas (STS). Patients presenting with large, high-grade, localized LMS are at significant risk of developing metastasis following curative surgery. Clinical trials of neoadjuvant or adj...

see more →

News  360 results

Efforts to Target NRG1 Unlock New Pathways for Treatment
https://www.onclive.com/view/efforts-to-target-nrg1-unlock-new-pathways-for-treatment

Mar 1st, 2022 - The advent and implementation of advanced sequencing technologies in clinical practice have aided in the identification of highly active oncogenic gene fusions. RNA sequencing has illuminated the presence of NRG1 fusions, which, though rare, play ...

Dr. Tap on Developing Treatment Opportunities in Soft Tissue Sarcomas
https://www.onclive.com/view/dr-tap-on-developing-treatment-opportunities-in-soft-tissue-sarcomas

Feb 2nd, 2022 - William D. Tap, MD, medical oncologist, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses developing treatment opportunities in soft tissue sarcomas. Soft tissue sarcomas represent approximately 80 diffe...

Paclitaxel-Carboplatin Established as Standard of Care for Uterine Carcinosarcoma
https://www.medpagetoday.com/hematologyoncology/othercancers/96856

Jan 25th, 2022 - Median overall survival (OS) and progression-free survival (PFS) in uterine carcinosarcoma (UCS) both improved with paclitaxel and carboplatin as compared with a standard-of-care regimen, a randomized trial showed. OS improved from 29 months with ...

Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma
https://www.onclive.com/view/meyer-characterizes-current-approaches-to-diagnosing-managing-and-studying-cardiac-angiosarcoma

Jan 10th, 2022 - Welcome to OncLiveOn Air®! I’m your host today, Jason Harris. OncLiveOn Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and prin...

Devimistat Plus Hydroxychloroquine Shows Early Promise in Relapsed Clear Cell Sarcoma
https://www.onclive.com/view/devimistat-plus-hydroxychloroquine-shows-early-promise-in-relapsed-clear-cell-sarcoma

Jan 7th, 2022 - No dose-limiting toxicities (DLTs) have been reported in the first cohort of patients with relapsed clear cell sarcoma who received the combination of devimistat (CPI-613) and hydroxychloroquine in the dose-escalation portion of the ongoing phase ...

see more →

Patient Education  27 results see all →